Intact Vascular raised nearly $4.7 million of an anticipated $9 million funding round, according to a regulatory filing. The company did not disclose details. In October, the Wayne, PA-based operation concluded enrollment in a 138-patient multicenter study testing its Tack-It endovascular stapler system in the superficial femoral and popliteal arteries after angioplasty for peripheral artery disease. A $15.5 million Series A round completed in September 2012 helped back the just-completed trial. Tack-It is a permanent catheter implant with four self-expanding tacks intended to optimize angioplasty by creating tissue apposition to smooth the arterial lumen. The device has had a CE mark since April 2012. Quaker Partners and H.I.G. BioVentures are among Intact's investors. Filing | Coverage